Peer-influenced content. Sources you trust. No registration required. This is HCN.
ReachMD
“If I can put smarter MRI adjacent to a robotic consult and seamlessly transfer from one image to the next, it allows me to have a very efficient, safe surgery, and ensure that I’ve removed all fibroids.” – Dr. Tamatha Fenster, New York-Presbyterian
Obstetrics & Gynecology March 26th 2026
Cancer Therapy Advisor
“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026
Oncology, Radiation March 17th 2026
Renal & Urology News
“At 10 years, BCF was 38.0% for HDR compared with 10.4% for SBRT.” — Udovicich et al., JAMA Network Open, February 2026
“The WOLVERINE meta-analysis provides the strongest evidence to date that MDT improves progression-free survival, radiographic progression-free survival, and castration resistance-free survival.” — Tang et al., The Lancet Oncology
Oncology, Medical February 17th 2026
Annals of Internal Medicine
Despite the scale of prostate-specific antigen (PSA) testing for prostate cancer screening, prediction models do not predict time-to-event end points or adjust for patient life expectancy.
Family Medicine/General Practice February 6th 2026
MedCentral
“The pain may not correlate with the extent of the disease. A patient with severe endometriosis may report little pain while someone with little extent of disease may report much pain.”
Obstetrics & Gynecology January 13th 2026